Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Short term Debt (2021)

MoonLake Immunotherapeutics' Short term Debt history spans 1 years, with the latest figure at $15.0 million for Q4 2021.

  • Quarterly Short term Debt changed N/A to $15.0 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2021, changed N/A year-over-year, with the annual reading at $15.0 million for FY2021, N/A changed from the prior year.
  • Short term Debt came in at $15.0 million for Q4 2021.
  • In the past five years, Short term Debt ranged from a high of $15.0 million in Q4 2021 to a low of $15.0 million in Q4 2021.